Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:NVAX 6 November 2025 - 31 January 2026

Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax shares fell 6.4% to $8.85 at Friday’s close, underperforming the broader market. Trading volume topped 5 million shares, above the 50-day average. Investors are watching for updates on partner-driven cash, including a $30 million upfront payment expected in Q1 2026 from a license deal. Novavax delayed its profitability target to 2028 and projects 2026 adjusted revenue of $185–$205 million.
31 January 2026
····
Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer shares closed up 0.8% at $26.10 Thursday, trading between $25.75 and $26.31. The gain followed news of a non-exclusive deal with Novavax for access to its Matrix‑M adjuvant, worth $30 million upfront. U.S. officials have reversed universal vaccine recommendations, shifting to “shared clinical-decision-making.” Pfizer CEO Albert Bourla blamed policy rhetoric for falling vaccination rates.
23 January 2026
···
Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer shares rose 0.8% to $25.73 Wednesday after the company agreed to exit its ViiV Healthcare stake, with Shionogi paying $1.875 billion and raising its holding to 21.7%. Pfizer also secured rights to Novavax’s Matrix-M adjuvant for $30 million upfront. Both deals await regulatory clearance and do not guarantee near-term earnings growth. Investors await Pfizer’s Q4 results on Feb. 3.
21 January 2026
····
NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

Novavax (NASDAQ: NVAX) closed at $6.91 on December 5, 2025, with a market cap near $1.1 billion. Shares are down about 20% over the past year and 94% over five years. Q2 2025 saw a surprise profit on $239 million revenue, boosted by a $175 million Sanofi milestone payment, but Q3 revenue dropped to $70 million with a net loss of $202 million. The stock trades 40% below its January high.
7 December 2025
Novavax Stock (NVAX) on November 24, 2025: Price, Sanofi Deal, Shah Capital Pressure and What It All Means for Investors

Novavax Stock (NVAX) on November 24, 2025: Price, Sanofi Deal, Shah Capital Pressure and What It All Means for Investors

Novavax (NASDAQ: NVAX) closed at $6.47 on Friday, up 4.0% but still 44% below its 52-week high. Q3 revenue beat estimates at $70 million, though losses widened and profitability is now targeted for 2028. Shah Capital is pressuring for a sale and threatening a proxy fight. The company expanded its Sanofi partnership, securing $225 million in milestones this year.
24 November 2025
·
Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax raised its FY2025 adjusted revenue outlook to $1.04–$1.06 billion after reporting Q3 revenue of $70 million, above estimates. The company posted a GAAP net loss of $202 million for the quarter, impacted by $126 million in non-cash charges tied to Maryland site consolidation and debt. Two $25 million milestone payments from Sanofi will be recognized in Q4. Cash stood at $778 million as of September 30.
6 November 2025
·····
Go toTop